High incidence of active cytomegalovirus infection among septic patients

Clinical Infectious Diseases

Volumn 26, Issue 5, 1998, Pages 1076-1084

  Kutza, Astrid S T ^b   Muhl, Elke ^b   Hackstein, Holger ^b   Kirchner, Holger ^b   Bein, Gregor ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS;

EID: 0031954760     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520307     Document Type: Article

References (24)

1. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;108:585-94.
2. Son JW van, The TH. Cytomegalovirus infection after organ transplantation: an update with special emphasis on renal transplantation. Transplant Int 1989;2:147-64.
3. Ho M. Epidemiology of cytomegalovirus infection in man. In: Cytomegalovirus, biology and infection. 2nd ed. New York: Plenum Medical Book, 1991:155-87.
4. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994;154:26-34.
5. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N EngI J Med 1987;317:659-65.
6. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8.
7. Cowley HC, Bacon PJ, Goode HF, Webster NR, Jones JG, Menon DK. Plasma antioxidant potential in severe sepsis: a comparison of survivors and nonsurvivors. Crit Care Med 1996;24:1179-83.
8. Brun-Buisson C, Doyon F, Carlet J, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA 1995;274:968-74.
9. Mayer J, Hajek R, Vorlicek J, Tomiska M. Sepsis and septic shock. Support Care Cancer 1995;3:106-10.
10. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457-69.
11. Stein J, Volk H-D, Liebenthal C, Krüger DH, Prösch S. Tumor necrosis factor a stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Virol 1993;74:2333-8.
12. Haagmans BL, Stals FS, van der Meide PH, Bruggeman CA, Horzinek MC, Schijns VECJ. Tumor necrosis factor a promotes replication and pathogenicity of rat cytomegalovirus. J Virol 1994;68:2297-304.
13. Haagmans BL, van den Eertwegh AJM, Claassen E, Horzinek MC, Schijns VECJ. Tumor necrosis factor a production during cytomegalovirus infection in immunosuppressed rats. J Gen Virol 1994;75:779-87.
14. Smith PD, Saini SS, Raffeld M, Manischewitz JF, Wahl SM. Cytomegalovirus induction of tumor necrosis factor-α by human monocytes and mucosal macrophages. J Clin Invest 1992;90:1642-8.
15. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci 1990;87:782-5.
16. Döcke WD, Prösch S, Fietze E, et al. Cytomegalovirus reactivation and tumor necrosis factor. Lancet 1994;343:268-9.
17. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
18. The TH, van der Ploeg M, van den Berg AP, Vlieger AM, van der Giessen M, van Son WJ. Direct detection of cytomegalovirus in peripheral blood leukocytes - a review of the antigenemia assay and polymerase chain reaction. Transplantation 1992;54:193-8.
19. Bitsch A, Kirchner H, Dupke R, Bein G. Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion 1992;32:612-7.
20. Bitsch A, Kirchner H, Dennin R, et al. The long persistence of CMV DNA in the blood of renal transplant patients after recovery from CMV infection. Transplantation 1993;56:108-13.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
22. Bein G, Bitsch A, Hoyer J, Kirchner H. The detection of human cytomegalovirus immediate early antigen in peripheral blood leucocytes. J Immunol Methods 1991;137:175-80.
23. Bein G, Bitsch A, Hoyer J, et al. A longitudinal prospective study of cytomegalovirus pp65 antigenemia in renal transplant recipients. Transpl Int 1993;6:185-90.
24. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene 1990;93:125-8.